Search
Methyldopa
go.drugbank.com/drugs/DB00968ApprovedInvestigationalMethyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals. … [A231784] It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects.
Zapomeran
go.drugbank.com/drugs/DB21761Approved[L52585,L52590] Previously marketed in Japan, in December 2024 Kostaive became the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission.[L52580,L52585] … [L52580,L52390] The self-amplifying nature of the vaccine is due to the mRNA additionally encoding a replicase enzyme, which creates more copies of the mRNA itself once inside the cell.
Diazoxide
go.drugbank.com/drugs/DB01119ApprovedInvestigational[A190372] Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. … [A190372] When administered intravenously, diazoxide can be used to treat hypertensive emergencies;[L44622] however, this specific form of diazoxide is no longer available in the US.
Ataluren
go.drugbank.com/drugs/DB05016ApprovedWithdrawnAtaluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk. … More specifically, ataluren is used in the small group of patients whose disease is caused by a specific genetic defect (called a ‘nonsense mutation’) in the dystrophin gene.
Melphalan flufenamide
go.drugbank.com/drugs/DB16627ApprovedWithdrawnIt has since been withdrawn from the market in the wake of the phase 3 OCEAN trial which showed a decrease in overall survival in comparison to standard treatment with [pomalidomide] and [dexamethasone … [A230123,L32173] Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases.
Methotrimeprazine
go.drugbank.com/drugs/DB01403ApprovedIt has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. … (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeCorynebacterium diphtheriae
go.drugbank.com/drugs/DB09877ApprovedInvestigationalThe vaccine is intramuscularly administered to provide active immunization against diphtheria in infants and children. … *Corynebacterium diphtheriae* toxin is extracted from the pathogenic actinobacterium *C. diphtheriae* that causes diphtheria.
Mixtures: Td-pur für Erwachsene und HeranwachsendePhysostigmine
go.drugbank.com/drugs/DB00981ApprovedIt can be applied topically to the conjunctiva. … It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.
Aripiprazole lauroxil
go.drugbank.com/drugs/DB14185ApprovedD2 receptors have been the most common target for antipsychotic agents used in the treatment of schizophrenia: the positive symptoms are thought to arise from overactivity in the mesolimbic dopaminergic … Aripiprazole lauroxil was initially approved by the FDA in October 2015 under the market name Aristada for the treatment of schizophrenia.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeAflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigational[A261281,A261286] Due to the 2 fused VEGFR, aflibercept has a higher affinity to the cognate ligands than the endogenous individual receptor. … [L47966,L47971] The intravitreal formulation, under the brand name EYELEA, was approved by the FDA for the treatment of retinopathy of prematurity in preterm infants in February 2023 and for the treatment